Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Boston Scientific Corporation (BSX) Halal?

PASS

Boston Scientific Corporation · NYSE: BSX · Healthcare

The short answer

Yes - Boston Scientific Corporation (BSX) passes this Shariah stock screen on all three gates. It is a pure medical-device company with two reportable segments, MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (interventional cardiology, Watchman, electrophysiology, cardiac rhythm management, oncology devices) - no alcohol, gambling, tobacco, or conventional-finance segments are disclosed. Interest-bearing debt of $12,624M at June 30, 2026 (company-stated) is about 20.2% of its ~$62.6B market cap ($43.23, October 1, 2026), below the ~33% ceiling. Interest income of $46M for the twelve months ended June 30, 2026 (disclosed in the company's own EBITDA reconciliation) is about 0.22% of $20,996M in revenue, below the 5% ceiling. Musaffa classifies BSX as halal as of October 2026; Zoya also covers BSX; no ShariaPortfolio rating was found - honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

Boston Scientific Corporation (NYSE: BSX) is a pure medical-device company headquartered in Marlborough, Massachusetts. It reports two segments: MedSurg (Endoscopy $2,916M, Urology $2,709M, Neuromodulation $1,199M in FY2025 - segment total $6,824M, 34% of net sales) and Cardiovascular (Interventional Cardiology & Vascular Therapies $4,639M, Watchman $1,958M, Electrophysiology $3,325M, Cardiac Rhythm Management $2,332M, Interventional Oncology & Embolization $996M - segment total $13,250M, 66%), on FY2025 total net sales of $20,074M. In Q2 2026 the company reported net sales of $5,442M - MedSurg $1,818M, Cardiovascular $3,624M. Haram check (factual, from company filings and releases): every product line is a medical device for cardiovascular, endoscopy, urology, neuromodulation, or oncology care - no alcohol, gambling, tobacco, entertainment, or conventional-finance segments are disclosed anywhere in the company's reporting. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Boston Scientific's Q2 2026 Financial & Operational Highlights (July 29, 2026) states total debt of $12,624M at June 30, 2026 in its reconciliation of Debt to Adjusted EBITDA - up from $11,029M at March 31, 2026 after a completed $2B accelerated share repurchase and a $1.5B investment in MiRus LLC. Against a market cap of about $62.6B ($43.23 close on October 1, 2026 times about 1.447B shares outstanding; Finnhub live market cap $63.04B), debt divided by market cap is about 20.2%, comfortably below the ~33% ceiling. Cash and cash equivalents of $539M at June 30, 2026 (10-Q XBRL filing data) are about 0.9% of market cap. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Boston Scientific's income-statement face carries no separate interest-income line (Other income (expense) shows only Interest expense and Other, net), but the company's own Q2 2026 Financial & Operational Highlights discloses Interest income as a separate line in its EBITDA reconciliation: $11M in Q2 2026 and $46M for the twelve months ended June 30, 2026 ($6M + $14M + $15M + $11M for Q3 2025 through Q2 2026). Against twelve-month revenue of $20,996M ($5,065M + $5,286M + $5,203M + $5,442M for the same four quarters, all from company releases), interest income is about 0.22% of revenue - far below the 5% non-compliant income ceiling. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does Boston Scientific do?

Boston Scientific Corporation (NYSE: BSX), headquartered in Marlborough, Massachusetts, is a global medical technology company that develops, manufactures, and markets devices used to diagnose and treat a broad range of medical conditions. It reports two segments: MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (interventional cardiology and vascular therapies, Watchman, electrophysiology, cardiac rhythm management, interventional oncology and embolization). For full-year 2025 the company reported net sales of $20,074M - MedSurg $6,824M (34%) and Cardiovascular $13,250M (66%). In Q2 2026 net sales were $5,442M - MedSurg $1,818M and Cardiovascular $3,624M.

Why does Boston Scientific pass this Shariah stock screen?

Boston Scientific passes all three gates of this screen. Gate 1 (business activity): it is a pure medical-device company - its two reportable segments, MedSurg and Cardiovascular, cover endoscopy, urology, neuromodulation, interventional cardiology, electrophysiology, cardiac rhythm management, and oncology devices, with no alcohol, gambling, tobacco, conventional finance, or other non-compliant segments disclosed. Gate 2: interest-bearing debt of $12,624M (company-stated debt at June 30, 2026) is about 20.2% of its ~$62.6B market cap ($43.23 close, October 1, 2026), below the ~33% ceiling. Gate 3: interest income of $46M over the twelve months ended June 30, 2026 is about 0.22% of $20,996M in revenue, below the 5% ceiling. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

What is Boston Scientific's interest-bearing debt ratio?

Boston Scientific's Q2 2026 Financial & Operational Highlights (July 29, 2026) states total debt of $12,624M at June 30, 2026 in its reconciliation of Debt to Adjusted EBITDA - up from $11,029M at March 31, 2026 after a completed $2B accelerated share repurchase and a $1.5B investment in MiRus LLC. Against a market cap of about $62.6B ($43.23 close on October 1, 2026 times about 1.447B shares outstanding per YCharts; Finnhub live market cap $63.04B gives the same picture), debt divided by market cap is about 20.2% - comfortably below the ~33% ceiling. Cash and cash equivalents of $539M at June 30, 2026 (10-Q XBRL filing data) are about 0.9% of market cap.

What is Boston Scientific's non-compliant income ratio?

Boston Scientific's income statements do not carry a separate interest-income line on their face (Other income (expense) shows only Interest expense and Other, net), but the company's own Q2 2026 Financial & Operational Highlights discloses Interest income as a separate line in its EBITDA reconciliation: $11M in Q2 2026 and $46M for the twelve months ended June 30, 2026 ($6M + $14M + $15M + $11M for Q3 2025 through Q2 2026). Against twelve-month revenue of $20,996M ($5,065M + $5,286M + $5,203M + $5,442M for the same four quarters, all from company releases), interest income is about 0.22% of revenue - far below the 5% non-compliant income ceiling. Gate 3 passes.

Do Zoya, Musaffa, or ShariaPortfolio cover Boston Scientific?

Musaffa covers BSX and classifies it as halal as of October 2026 (musaffa.com/stock/BSX/). Zoya also covers BSX (zoya.finance/stocks/bsx) - its page indicates a Shariah-compliant assessment based on the company's most recent reports, though the status and review date did not render in the page text fetched, so the current Zoya rating could not be confirmed here; Zoya's FAQ notes no separate interest-income line on the FY2025 10-K income-statement face. No ShariaPortfolio screening page or rating for BSX was found - reported as absent, not invented. This page applies the screen directly from Boston Scientific's own disclosures and reports these positions honestly.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).